1-piperidinecarboxamide

1-piperidinecarboxamide Uses, Dosage, Side Effects, Food Interaction and all others data.

1-piperidinecarboxamide is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. If FDA approved, it will join other previously-approved "-gepant" drugs rimegepant and ubrogepant as an additional treatment alternative for patients with migraine, particularly those for whom traditional triptan therapy has proven ineffective.

On April 15th, 2020, a phase 2 clinical trial (NCT04346615: Safety and Efficacy Trial of 1-piperidinecarboxamide Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen) began to investigate the use of intranasally administered vazegepant to combat the acute respiratory distress syndrome (ARDS) sometimes seen in patients with COVID-19. Acute lung injury activates the release of CGRP, which plays a role in the development of ARDS - CGRP antagonists, then, may help to blunt the significant inflammation associated with COVID-19. The clinical trial is expected to complete in September 2020.

Trade Name	1-piperidinecarboxamide
Generic	Vazegepant
Vazegepant Other Names	1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-, Zavegepant
Type
Formula	C36H46N8O3
Weight	Average: 638.817 Monoisotopic: 638.369287373
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here 1-piperidinecarboxamide